- Home
- HOWL
as of 01-23-2026 3:59pm EST
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 64.5M | IPO Year: | 2021 |
| Target Price: | $7.00 | AVG Volume (30 days): | 576.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.53 - $2.38 | Next Earning Date: | 03-10-2026 |
| Revenue: | N/A | Revenue Growth: | -90.55% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered HOWL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Werewolf Therapeutics Inc. (HOWL)
Director
Avg Cost/Share
$0.54
Shares
38,782
Total Value
$20,942.28
Owned After
2,159,860
SEC Form 4
Director
Avg Cost/Share
$0.55
Shares
37,413
Total Value
$20,577.15
Owned After
2,159,860
SEC Form 4
Director
Avg Cost/Share
$0.57
Shares
30,616
Total Value
$17,451.12
Owned After
2,159,860
SEC Form 4
Director
Avg Cost/Share
$0.55
Shares
43,198
Total Value
$23,758.90
Owned After
2,159,860
SEC Form 4
Director
Avg Cost/Share
$0.57
Shares
58,980
Total Value
$33,618.60
Owned After
2,159,860
SEC Form 4
Director
Avg Cost/Share
$0.61
Shares
24,678
Total Value
$15,053.58
Owned After
2,159,860
SEC Form 4
Director
Avg Cost/Share
$0.63
Shares
7,716
Total Value
$4,861.08
Owned After
2,159,860
SEC Form 4
Director
Avg Cost/Share
$0.64
Shares
11,915
Total Value
$7,625.60
Owned After
2,159,860
SEC Form 4
Director
Avg Cost/Share
$0.65
Shares
40,761
Total Value
$26,494.65
Owned After
2,159,860
SEC Form 4
Director
Avg Cost/Share
$0.64
Shares
18,378
Total Value
$11,761.92
Owned After
2,159,860
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| EVNIN LUKE | HOWL | Director | Jan 16, 2026 | Sell | $0.54 | 38,782 | $20,942.28 | 2,159,860 | |
| EVNIN LUKE | HOWL | Director | Jan 15, 2026 | Sell | $0.55 | 37,413 | $20,577.15 | 2,159,860 | |
| EVNIN LUKE | HOWL | Director | Jan 14, 2026 | Sell | $0.57 | 30,616 | $17,451.12 | 2,159,860 | |
| EVNIN LUKE | HOWL | Director | Jan 13, 2026 | Sell | $0.55 | 43,198 | $23,758.90 | 2,159,860 | |
| EVNIN LUKE | HOWL | Director | Jan 12, 2026 | Sell | $0.57 | 58,980 | $33,618.60 | 2,159,860 | |
| EVNIN LUKE | HOWL | Director | Jan 9, 2026 | Sell | $0.61 | 24,678 | $15,053.58 | 2,159,860 | |
| EVNIN LUKE | HOWL | Director | Jan 8, 2026 | Sell | $0.63 | 7,716 | $4,861.08 | 2,159,860 | |
| EVNIN LUKE | HOWL | Director | Jan 7, 2026 | Sell | $0.64 | 11,915 | $7,625.60 | 2,159,860 | |
| EVNIN LUKE | HOWL | Director | Jan 6, 2026 | Sell | $0.65 | 40,761 | $26,494.65 | 2,159,860 | |
| EVNIN LUKE | HOWL | Director | Jan 5, 2026 | Sell | $0.64 | 18,378 | $11,761.92 | 2,159,860 |
Compare HOWL vs Leading Stocks
See how HOWL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HOWL Werewolf Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.